Inovio Pharmaceuticals, Inc. Q1 FY2026 earnings call

• Lead Candidate Regulatory Progress

  • The Biologics License Application (BLA) for INO3107, a candidate for recurrent respiratory papillomatosis (RRP), remains on track for an October 30, 2026 PDUFA review date under the FDA's Accelerated Approval Program
  • The FDA has completed mid-cycle review with no new significant issues identified, and has reconfirmed intent to schedule an informal meeting to discuss INO3107's accelerated approval eligibility, first noted as a potential review issue in the BLA acceptance letter
  • Management believes INO3107 meets accelerated approval criteria: it reduces surgery frequency, has a favorable safety profile without required interim surgeries to maintain minimal residual disease, and a differentiated mechanism of action that works for patients unresponsive to the already approved competing therapy
  • An updated confirmatory trial protocol required for accelerated approval has been submitted to the IND, and the company is awaiting FDA feedback

• Commercial Preparation

  • Inovio plans to self-commercialize INO3107 in the U.S. with support from a contract sales organization if approved
  • All key commercial partners (third-party logistics, specialty distributor, patient hub, etc.) have been identified or engaged, and targeting, segmentation, and product positioning work is complete
  • The company is incorporating learnings from the recently launched competing RRP product into its commercial plans, and highlights that INO3107 avoids key competitor challenges: no requirement for ultra-cold chain storage and no required interim surgeries during dosing
  • Physician outreach at key medical conferences confirms strong unmet need and receptivity to additional RRP treatment options

• Pipeline and Platform Development

  • A new collaboration with Akizo Inc. has been launched to evaluate INO5412 in combination with Akizo's novel dual checkpoint inhibitor for glioblastoma (GBM), as part of a Dana-Farber Cancer Institute-sponsored Phase II adaptive platform trial
  • Promising preclinical data for the company's D-Prot (DNA-encoded protein) next-generation platform, targeting Factor VIII production for Hemophilia A, was presented at major conferences, and two new rare disease indications (Fabry disease and hypophosphatasia) have been added to the platform development pipeline
  • Management continues to use a partnership-focused strategy to advance pipeline candidates outside of INO3107 to conserve resources for the lead candidate

Inovio does not report separate revenue-generating product segments in this Q1 2026 earnings call, as the company is still in clinical development with no approved products generating revenue as of the quarter. Q1 2026 aggregate financial results are: total operating expenses of $21.9 million, a 13% decrease from $25.1 million in Q1 2025; net loss of $19.7 million ($0.28 per basic/dilutive share), equal to the Q1 2025 net loss of $19.7 million ($0.51 per basic/dilutive share). As of March 31, 2026, the company held $37.7 million in cash, cash equivalents, and short-term investments, compared to $58.5 million as of December 31, 2025. An April 2026 underwritten public equity offering added $16 million in net proceeds post-expenses.

• The company expects operational net cash burn of approximately $18 million for the second quarter of 2026
• Including the net proceeds from the April 2026 public equity offering, Inovio estimates its current cash resources are sufficient to fund operations into the first quarter of 2027, which extends cash runway beyond INO3107's October 2026 PDUFA date
• Cash runway projections do not include any potential future capital raises and are based on current operating assumptions

• All forward-looking statements regarding INO3107's regulatory approval, launch, and commercial performance carry inherent uncertainty, including the FDA's final determination of accelerated approval eligibility and the outcome of the upcoming informal meeting and confirmatory trial feedback
• Actual clinical, regulatory, and financial results could differ materially from management's current expectations, due to risk factors outlined in Inovio's periodic SEC filings
• There is uncertainty around whether the recently resigned FDA commissioner will impact INO3107's review timeline, though management noted the review is proceeding as planned to date
• Commercial success depends on market acceptance of INO3107 in competition with the already approved RRP therapy, and penetration of the currently underpenetrated RRP patient market

Q: How does Inovio plan to differentiate INO3107 from the already marketed competing RRP product and capture market share at launch? / A: Management notes INO3107 has a positively differentiated profile across efficacy, tolerability, and regimen simplicity. Most published patient population estimates are outdated and undercount total RRP cases, and the competing product is expected to have only single-digit market penetration by the time INO3107 launches, leaving the vast majority of the market opportunity open. Inovio will incorporate learnings from the competitor's launch into its go-to-market plan as a fast-following second entrant, a position that has historically led to strong market performance in many cases.

Q: What key topics will Inovio discuss at the upcoming informal FDA meeting about INO3107, and what is the status of the confirmatory trial protocol? / A: The primary topic of discussion will be confirming INO3107's eligibility for accelerated approval, focused on demonstrating INO3107 provides meaningful therapeutic benefit over existing treatments. Management will emphasize INO3107's safety advantage (no required minimal residual disease surgeries) and differentiated mechanism that works for patients unresponsive to the competing product, due to pre-existing neutralizing antibodies that do not impact INO3107. Feedback on the confirmatory trial protocol is expected to be tied to the outcome of the informal meeting, linked to the final review pathway decision.

Q: Is there any expectation that the recent FDA commissioner resignation will introduce uncertainty to INO3107's review timeline? / A: Management declined to comment on internal FDA operations, but stated the INO3107 review is proceeding on schedule: the FDA completed mid-cycle review without issues, reconfirmed the plan for the informal meeting, and the company continues to respond to all agency information requests as scheduled.

Q: What is Inovio's expectation for the INO3107 label at approval, specifically regarding eligible patient population restrictions? / A: Management expects a label very similar to the already approved competing RRP product, with no anticipated eligibility restrictions relative to the Phase I-II trial population. The INO3107 trial enrolled patients across a range of disease severities (2 to 8 prior surgeries in the year before enrollment) with a balance of HPV 6, HPV 11, and combined infections, and the mechanism of action does not suggest any difference in efficacy based on disease severity, so no restrictions are expected.